Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
Status:
Completed
Trial end date:
2008-06-05
Target enrollment:
Participant gender:
Summary
This is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of
doses of GSK189075 (an SGLT2 inhibitor) compared to placebo, administered over 12 weeks in
treatment-naive subjects with type 2 diabetes mellitus